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There is concern the Coronavirus Disease (COVID)-19 pandemic is having a negative impact on the
mental health of the general population through a range of suggested mechanisms: fear, uncertainty,
and anxiety; social distancing/isolation; loneliness; and economic repercussions (1–3). Previous
disasters such as the Severe Acute Respiratory Syndrome (SARS) in 2003 (4–6) contributed to
increased anxiety, mood, and thought disorders, adjustment disorders, and post-traumatic stress
disorders (PTSD) (1, 7–15), resulting, in extreme cases, in suicidal behaviours (e.g., suicidal ideation,
suicide attempts, and actual suicide) (10, 16), especially in cases of concomitant Substance Use
Disorder (SUD) (17, 18). According to a recent study from the Well Being Trust (18) the high levels
of stress, isolation and unemployment due to the COVID-19 pandemic could cause up to 75,000
“deaths of despair” related to deaths to drug, alcohol, and suicide (18). High risk of mental illness
was previously identified in individuals with existing or history of mental illnesses (1, 9, 12, 14, 19),
but also vulnerable categories might be considered the elderly (>80 years old), children/adolescents,
individuals from deprived areas, peri-natal women and BAME (Black, Asian and minority
ethnicities) (1, 12, 14, 19). Finally, healthcare workers have been experiencing emotional
overload due to several reasons, including both organizational issues relating to the shortage of
suitable personal protective equipment, reduction in human resources and relentless work shifts
(20–23), but also the burden developed by the fear of becoming infected and infecting relatives, high
mortality rates, grieving the loss of patients and colleagues, separation from families (22–24).
Specifically, according to Huang et al. (25), among the first-line medical staff of a Tertiary Infectious
Disease Hospital for COVID-19 in China, the incidence of anxiety and post traumatic symptoms in
female medical staff was higher than that in male, and in nurses more represented than that in
doctors (25).DISCUSSION
Often overlooked in this scenario are those with SUD (26, 27), who may experience: (a) changes in
levels of drug use—an increase is often seen as a reactive behaviour to negative impact of disasters;
(b) a shift to other substances if access to those previously used become limited; (c) a relapse, if they
had already recovered from alcohol/drug addiction. Risks of severe COVID and intensified mentalg July 2020 | Volume 11 | Article 7671
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comorbidity, e.g., lung or cardiovascular disease, HIV, viral
hepatitis infections; psychological comorbidity, e.g., general
distress, sleep disorders, anxiety/mood disorders, psychotic
symptoms; and homelessness, incarceration, economic
difficulties, and socioeconomic issues deriving from drug
addiction (8, 11, 27, 28). Overdose risk for addicted people
who are home-isolating, and hence with typically no one to
inject them with naloxone, should be considered in a time of
overloaded emergency services and healthcare systems in general
(27, 29). The COVID-19 pandemic is already impacting drug
markets, including shortages of numerous types of drugs at the
street level, price increases for consumers on the black market
and reductions in purity. Synthetic drugs’ availability, such as
methamphetamine, is drastically reduced due to air travel
restrictions and flight cancellations, while cocaine, mostly
trafficked by sea, continues to be detected in European ports
during the pandemic (30). Heroin and opioids seem to be
pushed toward being trafficked along maritime routes. Finally,
cannabis appears to be less available, due to restrictions on
movement across regions and borders under coronavirus
lockdown. These disruptions are likely to grow and further
increase risks for people who use drugs, for example by
increasing variability in drug purity, the likelihood of
adulteration, and contamination of heroin supply with
synthetic opioids, such as fentanyl. These issues can also
encourage shifts to more at-risk drug using behaviours such as
use of drugs such as street benzodiazepines, and synthetic
cannabinoids (31). Additionally, the COVID-19 crisis is likely
to increase the need to access drug treatment and services, e.g.,
extra demand for opioid substitution therapy and other
medication. Access to drug services is being disrupted by self-
quarantine, social distancing and other public health measures
adopted for dealing with COVID-19 (27, 29, 31). Similarly,
community pharmacies are challenged by staff shortages,
service disorganisation, and self-isolation (27, 29, 32).
In response to the long-lasting and wide-ranging challenging
effects of the pandemic (5, 12, 19, 27, 29), some harm-avoiding
interventions have been adopted, including: more flexible take-
home-medication treatment programmes for opioid addicted
patients (33, 34); guidance for facilitating controlled substance
prescribing (26, 29, 35); tele-health for monitoring drug-
dependent patients; and access to virtual support groups
through online meetings (15, 26, 32). Conversely, both peer-
support groups and rehabilitation facilities have suspended
programmes and limited new admissions (27, 32). Hollander &
Carr (36) compared and contrasted the acceptability and impact
of telemedicine versus in-person consultations. During the
COVID pandemic, telehealth has demonstrated to enable
continuity of services, while protecting service providers from
infection. However, in-person consultations are still needed for
certain groups of patients where maintenance in treatment is
at risk.
In this context, due to the disruption of drug markets,
reduced supply and access to illicit drugs, internet drug-
seeking activities may be on the increase. In line with this,Frontiers in Psychiatry | www.frontiersin.org 2rogue/illicit pharmaceutical products, such as benzodiazepines,
has also reportedly doubled their prices in some areas (24).
Alternative drugs or medications might be considered by users
including quetiapine, gabapentinoids, Z-drugs (e.g., zolpidem)
(37–39) and some Over-The-Counter (OTC) medications (37,
38), such as codeine; ephedrine and pseudoephedrine; and the
antidiarrhoeal loperamide (“poor man’s methadone”).IMPLICATIONS IN PRACTICE
Interventions addressing the health, psychological, and social
effects of the pandemic are required. Healthcare professionals
have an important role in educating patients about the common
psychological effects of a pandemic. COVID-19, together with
general environmental factors, such as stress or trauma, may
contribute to both a mental illness and a SUD developing. A
proactive approach to upscale our mental health care, emergency
preparedness and response for people with SUDs is urgently
needed; mental health services should develop and evaluate: clear
remote assessment; care pathways for people at risk; psycho-
education strategies, regarding self-harm/suicide, overdoses, and
domestic violence; and staff training to support new ways of
working (1, 7, 12). Healthcare providers, including pharmacists,
and public health policies are challenged to: develop strategies to
implement preventionmeasures against transmission of COVID-19
in drug users settings, such as preventing overcrowding or sharing
drug-using equipment; and ensure continuity of care for drug-users
and people with SUDs. Specifically, access to community
maintenance, e.g., expand methadone delivery via mobile teams
for quarantined patients should be facilitated (40, 41). Monitoring
psychosocial needs and delivering psychosocial support to
vulnerable patients as well as healthcare workers should be
provided (2, 3, 8, 42, 43). It is crucial to strengthen telemedicine
and support it with appropriate governance and funding in order to
be able to monitor the mental health situation post-pandemic.
Supporting healthcare workers with appropriate equipment,
training on telehealth and caring for their safety with respect to
protection against infection and spread of infection, preventing
violence and burglary in drug treatment services, pharmacies would
enable robust support against a possible mental health wave post-
pandemic. Prescribers and pharmacists should be warned about:
possible requests to prescribe more drugs than needed to take home;
excessive sales of prescription/OTC products which might be
diverted and abused; and aggression toward staff. Developing
multidisciplinary support platforms could be helpful in reducing
the mental distress due to misinformation and teaching problem-
solving strategies to cope with the pandemic (13).AUTHOR CONTRIBUTIONS
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